- Home
- OMER vs AMBC Comparison
OMER vs AMBC Comparison
Compare OMER & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- AMBC
- Stock Information
- Founded
- OMER 1994
- AMBC 1991
- Country
- OMER United States
- AMBC United States
- Employees
- OMER N/A
- AMBC N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- AMBC Property-Casualty Insurers
- Sector
- OMER Health Care
- AMBC Finance
- Exchange
- OMER Nasdaq
- AMBC Nasdaq
- Market Cap
- OMER 579.5M
- AMBC 635.7M
- IPO Year
- OMER 2009
- AMBC 1991
- Fundamental
- Price
- OMER $9.33
- AMBC $11.43
- Analyst Decision
- OMER Buy
- AMBC Strong Buy
- Analyst Count
- OMER 4
- AMBC 2
- Target Price
- OMER $22.50
- AMBC $17.00
- AVG Volume (30 Days)
- OMER 1.1M
- AMBC 629.7K
- Earning Date
- OMER 11-13-2024
- AMBC 02-25-2025
- Dividend Yield
- OMER N/A
- AMBC N/A
- EPS Growth
- OMER N/A
- AMBC N/A
- EPS
- OMER N/A
- AMBC N/A
- Revenue
- OMER N/A
- AMBC $398,000,000.00
- Revenue This Year
- OMER N/A
- AMBC N/A
- Revenue Next Year
- OMER N/A
- AMBC N/A
- P/E Ratio
- OMER N/A
- AMBC N/A
- Revenue Growth
- OMER N/A
- AMBC 22.46
- 52 Week Low
- OMER $2.61
- AMBC $10.12
- 52 Week High
- OMER $13.60
- AMBC $18.45
- Technical
- Relative Strength Index (RSI)
- OMER 49.55
- AMBC 39.54
- Support Level
- OMER $8.21
- AMBC $10.67
- Resistance Level
- OMER $11.26
- AMBC $11.80
- Average True Range (ATR)
- OMER 0.93
- AMBC 0.44
- MACD
- OMER -0.20
- AMBC -0.08
- Stochastic Oscillator
- OMER 31.37
- AMBC 35.02
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.